Ontology highlight
ABSTRACT:
SUBMITTER: Hwang JH
PROVIDER: S-EPMC6886683 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
Cell reports 20191101 8
Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open reading frame (ORF) expression screen and in tumor xenografts. CREB5 overexpression is essential for an enzalutamide-resistant patient-derived organoid. In AR-expressing prostate cancer cells, CREB5 intera ...[more]